THAT WHICH IS CLAIMED:

1. A compound with a structure of formula (III):



Formula (III)

wherein L is selected from

 ,  , and

 ,

wherein q, r, and v are independently selected from integers 0, 1, 2 and 3, and z is selected from integers 1, 2 and 3; and

A is selected from

 ,  , and  ,

wherein X_4 and X_7 are CR_3,

X_5 and X_6 are independently selected from CR_3 and N;

only one of X_5 or X_6, is N;

R_3 is -H;

m is 1 or 2; and

W is –O or –NR_4, wherein R_4 is selected from selected from -H and -CO(C_1-C_6 alkyl); or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein L is



wherein q and r are independently selected from integers 0, 1 and 2.

3. The compound of claim 2, wherein L is



, wherein q and r are 0 or 1.

4. The compound of claim 3, wherein m is 1 and W is selected from -NH and -N(C_1-C_6 alkyl)$_2$.

5. The compound of claim 4, wherein L is



, wherein z is selected from integers 1 or 2.

6. The compound of claim 5, wherein A is



.

7. The compound of claim 6, wherein A is  .

8. The compound of claim 7, wherein said compound has the structure:

 ,  , or  , or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, wherein the compound binds to a region of an RNA molecule.

10. The compound of claim 9, wherein the RNA molecule is a non-coding RNA molecule selected from rRNA, microRNAs, siRNAs, piRNAs, snoRNAs, snRNAs, exRNAs, and scaRNAs.

11. The compound of claim 9, wherein the RNA molecule is a coding RNA molecule selected from mRNA.

12. The compound of claim 11, wherein the region of the mRNA is a TPP riboswitch.

13. A composition comprising a therapeutically effective amount of the compound of claim 1 in a pharmaceutically acceptable carrier, diluent, or excipient.

14. A compound of claim 1 for use in the treatment of a disease or disorder is selected from genetic diseases, degenerative disorders, cancer, diabetes, autoimmune disorders, cardiovascular disorders, clotting disorders, diseases of the eye, infectious disease, and diseases caused by mutations in one or more gene, wherein the compound is to be administered to a subject in need thereof at a dose of a therapeutically effective amount of the compound.

15. The compound for use of claim 14, wherein the compound is to be administered to lower protein expression due to binding of the compound to RNA.

16. The compound for use of claim 14, wherein the disease or disorder is a genetic disease and the compound is to be administered to switch expression of a therapeutic gene on or off.